Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/20278Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Talbot, J. A. | en |
| dc.contributor.author | Shalet, S. M. | en |
| dc.contributor.author | Tsatsoulis, A. | en |
| dc.contributor.author | Grabinski, M. | en |
| dc.contributor.author | Robertson, W. R. | en |
| dc.date.accessioned | 2015-11-24T19:05:58Z | - |
| dc.date.available | 2015-11-24T19:05:58Z | - |
| dc.identifier.issn | 0105-6263 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/20278 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use | en |
| dc.subject | Cells, Cultured | en |
| dc.subject | Hodgkin Disease/*drug therapy | en |
| dc.subject | Humans | en |
| dc.subject | Leydig Cells/drug effects/*secretion | en |
| dc.subject | Luteinizing Hormone/*secretion | en |
| dc.subject | Male | en |
| dc.subject | Mechlorethamine/adverse effects/therapeutic use | en |
| dc.subject | Prednisolone/adverse effects/therapeutic use | en |
| dc.subject | Procarbazine/adverse effects/therapeutic use | en |
| dc.subject | Pulsatile Flow | en |
| dc.subject | Radioimmunoassay | en |
| dc.subject | Testosterone/blood | en |
| dc.subject | Vinblastine/adverse effects/therapeutic use | en |
| dc.title | Luteinizing hormone pulsatility in men with damage to the germinal epithelium | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/2387642 | - |
| heal.identifier.secondary | http://onlinelibrary.wiley.com/store/10.1111/j.1365-2605.1990.tb00980.x/asset/j.1365-2605.1990.tb00980.x.pdf?v=1&t=h0ouov8k&s=3c2e0ad393637e1cd3d2b261e8140195cf3016e9 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1990 | - |
| heal.abstract | Bioactive-LH (B-LH) was measured in plasma by in-vitro bioassay and immunoactive-LH (I-LH) by immunoassay at 10 min intervals for 6 h in five men after standard chemotherapy for Hodgkin's disease. Eleven normal men acted as controls. Follicle-stimulating hormone (FSH) was markedly raised in the treated patients (mean +/- SEM; 12.8 +/- 2.8 vs. 2.7 +/- 0.4 IU l-1, P less than 0.006) reflecting damage to the germinal epithelium. Bioactive (27.4 +/- 2.8 vs. 12.9 +/- 1.3 IU l-1) and I-LH (9.6 +/- 2.0 vs. 4.9 +/- 0.4 IU l-1) were elevated (P less than 0.006) in the patient group whilst testosterone levels (24.0 +/- 3.8 vs. 19.6 +/- 2.4 nmol l-1) were normal. The testosterone I-LH ratio, a putative index of Leydig cell dysfunction, was negatively correlated with FSH levels (r = -0.85, P less than 0.02). Bioactive and I-LH pulse peak amplitude were elevated, as were pulse maxima (P less than 0.05). In contrast, B-LH pulse frequency was similar between the patients (2 pulses per 6 h) and controls (median 2, range 1-3 pulses per 6 h) as was the I-LH pulse frequency (median 2, 1-2 pulses per 6 h in both groups). The mean B:I LH ratios were similar (2.94 +/- 0.09 vs. 2.63 +/- 0.14) in both groups, although the inter-pulse B:I ratio was increased (P less than 0.007) in the patient group.(ABSTRACT TRUNCATED AT 250 WORDS) | en |
| heal.journalName | Int J Androl | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Talbot-1990-Luteinizing hormone.pdf | 545.07 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
